Physician profile
Jaclyn Rose Geddes
NPI 1861053639
$8,830.83
in general payments reported to CMS, 2019-2025
16 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 98% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $1,072 · 2023: $1,178 · 2024: $2,149 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,726 · Travel and Lodging: $2,352 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,726.40 |
| Travel and Lodging | $2,352.23 |
| Education | $100.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,675.68 | 2021-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Medtronic, INC. | $1,354.76 | 2021-2025 | Linq II, Micra, In.Pact Av |
| Abbott Laboratories | $764.92 | 2024-2025 | Aveir, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals Lp | $595.56 | 2021-2025 | Farxiga, Atacand, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $591.35 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $479.24 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $95.38 | 2021-2024 | |
| Pfizer INC. | $84.75 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $45.94 | 2022-2024 | Xarelto |
| Amgen INC. | $33.81 | 2023-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $25.41 | 2023 | Optimizer |
| Daiichi Sankyo INC. | $24.10 | 2025 | Injectafer |
| Philips North America LLC | $16.11 | 2022 | |
| Ucb, INC. | $15.53 | 2023 | Briviact |
| Cardiva Medical, INC. | $14.57 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $13.72 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Geddes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.